Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

CYNAMIS Clonal dynamics and mitochondrial dysfunction in hematopoiesis following chemotherapy

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 December 2024 to 30 November 2026
Status
Running
EU funding
€190k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101150135

What the project is doing

In the project's own words, from its summary on CORDIS.

Chemotherapy can cause significant damage to healthy tissues, especially in the hematopoietic system. As a result, cancer survivors may experience bone marrow damage manifested as cytopenias, which increase the risk of infections and bleeding. Despite this, there has not been a thorough examination of these events, including the clonal dynamics of hematopoiesis after chemotherapy exposure, due to a lack of methodologies to perform lineage tracing in humans in vivo.

To address this, I will study the effects of chemotherapy on the clonal dynamics of hematopoiesis, mitochondrial dysfunction and genetic integrity in young cancer survivors. I will analyze samples obtained before, during, and after treatment using emerging single-cell multi-omic approaches to effectively capture mitochondrial DNA (mtDNA) genetic variation for inferences of clonal dynamics and studies of mtDNA damage. By combining mtDNA-based clonal inferences with whole-genome sequencing (WGS)-based detection of somatic nuclear DNA mutations, I will provide deep phylogenies with scalable single-cell resolved clonal measurements of perturbed hematopoiesis following chemotherapy.

Moreover, orthogonal analysis of DNA methylation and chromatin accessibility data will yield new molecular insights into chemotherapy-induced accelerated aging and mitochondrial dysfunction (a hallmark of aging). This project sets out to gain quantitative and fundamental insights into the long-term molecular defects of chemotherapy in young cancer survivors, potentially paving the way for new interventions to improve the quality of life of this emergent population.

Topics

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI